It hasn't gone away: the problem of glucocorticoid use in lupus remains.

about

Corticosteroid-induced Osteonecrosis of the Femoral Head: Detection, Diagnosis, and Treatment in Earlier Stages.Systemic lupus erythematosus and ocular involvement: an overview.Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner.

P2860

Q47108762-94E5A354-218D-4F71-9C70-B43DEB115154 Q49833678-40161B9E-EB33-4074-A35A-1887A3B62D58 Q55282858-52EC1570-3602-41EB-97E4-C8903AC4CF5E

P2860

It hasn't gone away: the problem of glucocorticoid use in lupus remains.

Item

http://www.wikidata.org/entity/Q39053147

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

It hasn't gone away: the problem of glucocorticoid use in lupus remains.

@en

It hasn't gone away: the problem of glucocorticoid use in lupus remains.

@nl

type

Item

label

It hasn't gone away: the problem of glucocorticoid use in lupus remains.

@en

It hasn't gone away: the problem of glucocorticoid use in lupus remains.

@nl

prefLabel

It hasn't gone away: the problem of glucocorticoid use in lupus remains.

@en

It hasn't gone away: the problem of glucocorticoid use in lupus remains.

@nl

P1476

It hasn't gone away: the problem of glucocorticoid use in lupus remains

@en

P2093

Diane Apostolopoulos

http://www.w3.org/2001/XMLSchema#string

P2860

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

6-Thioguanine nucleotide accumulation in erythrocytes during azathioprine treatment for systemic connective tissue diseases: a possible index for monitoring treatment.

Premature coronary-artery atherosclerosis in systemic lupus erythematosus.

Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study.

Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis

Clinical associations of serum interleukin-17 in systemic lupus erythematosus.

P304

i114-i122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEW406

http://www.w3.org/2001/XMLSchema#string

P433

suppl_1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eric F. Morand

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28013208

http://www.w3.org/2001/XMLSchema#string

It hasn't gone away: the problem of glucocorticoid use in lupus remains.

about

P2860

P2860

It hasn't gone away: the problem of glucocorticoid use in lupus remains.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698